McKinley Carter Wealth Services Inc. trimmed its holdings in shares of Pfizer (NYSE:PFE) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,917 shares of the biopharmaceutical company’s stock after selling 2,702 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Pfizer were worth $902,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Chicago Equity Partners LLC lifted its holdings in Pfizer by 2.7% during the fourth quarter. Chicago Equity Partners LLC now owns 259,690 shares of the biopharmaceutical company’s stock valued at $9,406,000 after purchasing an additional 6,850 shares in the last quarter. Savant Capital LLC lifted its holdings in Pfizer by 4.4% during the fourth quarter. Savant Capital LLC now owns 54,941 shares of the biopharmaceutical company’s stock valued at $1,990,000 after purchasing an additional 2,300 shares in the last quarter. Telos Capital Management Inc. purchased a new position in shares of Pfizer in the fourth quarter worth $265,000. Callahan Advisors LLC lifted its holdings in shares of Pfizer by 0.7% in the fourth quarter. Callahan Advisors LLC now owns 291,717 shares of the biopharmaceutical company’s stock worth $10,566,000 after buying an additional 1,941 shares in the last quarter. Finally, Vigilant Capital Management LLC lifted its holdings in shares of Pfizer by 40.7% in the fourth quarter. Vigilant Capital Management LLC now owns 54,937 shares of the biopharmaceutical company’s stock worth $1,990,000 after buying an additional 15,895 shares in the last quarter. Institutional investors own 71.20% of the company’s stock.
Shares of PFE opened at $35.17 on Monday. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The firm has a market capitalization of $209,362.27, a P/E ratio of 13.27, a price-to-earnings-growth ratio of 1.76 and a beta of 0.90. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer declared that its board has authorized a share buyback plan on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.
In other Pfizer news, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the transaction, the director now owns 1,000 shares in the company, valued at $36,790. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 in the last 90 days. 0.06% of the stock is currently owned by company insiders.
Several research firms have recently commented on PFE. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. SunTrust Banks reissued a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Pfizer in a report on Monday, January 29th. Morgan Stanley boosted their target price on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. UBS set a $42.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $39.25.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.